XBI - Aeglea BioTherapeutics: Investment Potential Addressing Unmet Need
Today, we want to share our analysis of Aeglea BioTherapeutics (AGLE) with you. Recently, the company’s stock price grew by over 15% following the recent purchases by CEO Anthony G. Quinn. Aeglea BioTherapeutics offers an attractive combination of a debt-free balance sheet with ~50% of its market cap in cash and a promising pipeline. So, let’s consider this promising biotech in-depth.
Company description
Aeglea BioTherapeutics is a clinical-stage biotechnology company headquartered in the Austin that concentrates on developing human enzyme therapeutics for the treatment of rare genetic diseases and cancer. The company was